Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-243-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$92.01 million
Profitability
Miscellaneous
Employees270
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) announced its earnings results on Tuesday, July, 30th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.04. The biotechnology company earned $30.14 million during the quarter, compared to analyst estimates of $29.20 million. Veracyte had a negative return on equity of 10.26% and a negative net margin of 11.01%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What guidance has Veracyte issued on next quarter's earnings?
Veracyte issued an update on its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $119-122 million, compared to the consensus revenue estimate of $119.33 million.
What price target have analysts set for VCYT?
5 equities research analysts have issued 1-year price targets for Veracyte's shares. Their predictions range from $12.30 to $35.00. On average, they expect Veracyte's stock price to reach $24.5750 in the next twelve months. This suggests that the stock has a possible downside of 4.8%. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Has Veracyte been receiving favorable news coverage?
News stories about VCYT stock have trended positive on Tuesday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veracyte earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Veracyte.
Are investors shorting Veracyte?
Veracyte saw a drop in short interest in July. As of July 31st, there was short interest totalling 2,558,800 shares, a drop of 10.0% from the June 30th total of 2,842,700 shares. Based on an average daily trading volume, of 733,100 shares, the days-to-cover ratio is presently 3.5 days. Currently, 8.0% of the company's shares are sold short. View Veracyte's Current Options Chain.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Celcuity (CELC), Fulgent Genetics (FLGT), Enzo Biochem (ENZ), Psychemedics (PMD), PotNetwork (POTN), Miragen Therapeutics (MGEN), Biocept (BIOC) and Avant Diagnostics (AVDX).
What other stocks do shareholders of Veracyte own?
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
- Mr. Christopher M. Hall, Pres & COO (Age 50)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
- Mr. Ashish Kheterpal, Chief Information Officer
Who are Veracyte's major shareholders?
Veracyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.23%), ARK Investment Management LLC (7.29%), Invesco Ltd. (6.16%), Versant Venture Management LLC (5.79%), Vanguard Group Inc. (4.74%) and Nikko Asset Management Americas Inc. (5.16%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which major investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, ARK Investment Management LLC, First Light Asset Management LLC, D. E. Shaw & Co. Inc., Allianz Asset Management GmbH, Laurion Capital Management LP, Essex Investment Management Co. LLC and Cortina Asset Management LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy and Jesse I Treu. View Insider Buying and Selling for Veracyte.
Which major investors are buying Veracyte stock?
VCYT stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nikko Asset Management Americas Inc., BlackRock Inc., Nuveen Asset Management LLC, Fiera Capital Corp, Bamco Inc. NY, Vanguard Group Inc. and Sumitomo Mitsui Trust Holdings Inc.. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $25.82.
How big of a company is Veracyte?
Veracyte has a market capitalization of $1.25 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.
What is Veracyte's official website?
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
